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Background: The UKMedical Research Council ST03 trial compared perioperative epirubicin, cisplatin
and capecitabine (ECX) chemotherapy with or without bevacizumab (B) in gastric and oesophagogastric
junctional cancer. No difference in survival was noted between the arms of the trial. The present study
reviewed the standards and performance of surgery in the context of the protocol-specified surgical
criteria.
Methods: Surgical and pathological clinical report forms were reviewed to determine adherence to the
surgical protocols, perioperative morbidity and mortality, and final histopathological stage for all patients
treated in the study.
Results: Of 1063 patients randomized, 895 (84⋅2 per cent) underwent resection; surgical details were
available for 880 (98⋅3 per cent). Postoperative assessment data were available for 873 patients; complica-
tions occurred in 458 (52⋅5 per cent) overall, of whom 71 (8⋅1 per cent) developed complications deemed
to be life-threatening by the responsible clinician. The most common complications were respiratory
(211 patients, 24⋅2 per cent). The anastomotic leak rate was 118 of 873 (13⋅5 per cent) overall; among
those who underwent oesophagogastrectomy, the rate was higher in the group receiving ECX-B (23⋅6 per
cent versus 9⋅9 per cent in the ECX group). Pathological assessment data were available for 845 patients.
At least 15 nodes were removed in 82⋅5 per cent of resections and the median lymph node harvest was 24
(i.q.r. 17–34). Twenty-five or more nodes were removed in 49⋅0 per cent of patients. Histopathologically,
the R1 rate was 24⋅9 per cent (208 of 834 patients). An R1 resection was more common for proximal
tumours.
Conclusion: In the ST03 trial, the performance of surgery met the protocol-stipulated criteria. Regis-
tration number: NCT00450203 (http://www.clinicaltrials.gov).
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Introduction
Surgeons in East Asia established the extent of resec-
tion of the stomach and the philosophy of extended
lymphadenectomy1. However, whether this converts to a
survival benefit in all patients has been controversial. Sur-
gical resection for gastric and oesophagogastric junctional
(OGJ) cancer in non-Asian countries has also been vari-
able in extent. Most European studies have demonstrated
limited benefit for extended lymphadenectomy2,3, with
the exception of data from the long-term follow-up in
the Dutch trial4 which confirmed fewer cancer deaths
in the group treated by D2 dissection. Surgery for OGJ
cancers has evolved based on the classification described by
Siewert and colleagues5, in which patterns of lymph node
spread were defined according to tumour origin in relation
to the OGJ. Although some have promoted abdominal,
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mediastinal and cervical nodal dissection, particularly
for squamous cell carcinoma6, most surgeons combine
abdominal and posterior mediastinal nodal dissection into
a so-called two-field lymphadenectomy7.
This lack of consistency has led to global variability
in surgical approach and individual surgeon practice.
National guidelines8,9, based on evidence and expert
opinion, have been designed to promote consistency of
surgical practice and have recommended D2 dissection
and two-field lymphadenectomy in appropriately selected
patients with gastric and OGJ cancer respectively. Another
approach to assess and implement consistency of surgery
is to conduct multicentre trials where the type and extent
of surgery is prespecified in the trial protocol. In the
MAGIC (Medical Research Council (MRC) Adjuvant
Gastric Infusional Chemotherapy) trial10, surgeons were
recommended to resect local and regional perigastric
lymph nodes, and at least sample more distant lymph
nodes for staging. Based on this recommendation, the D2
resection rate in MAGIC was 41 per cent.
The MRC ST03 trial11 was designed to evaluate the
addition of bevacizumab, which targets vascular endothe-
lial growth factor, to the combination chemotherapy
regimen used in the MAGIC trial. The primary outcome
was overall survival, with secondary outcomes of macro-
scopic disease-free survival, progression-free survival,
response rates to preoperative chemotherapy and curative
(R0) resection rates. The study protocol described rec-
ommended surgical procedures and stipulated resection
of a minimum of 15 lymph nodes from specified lymph
node stations in order to meet the pathological staging
requirements of the UICC TNM classification seventh
edition12, with further nodal dissection according to the
individual surgeon’s discretion.
The aim of this report was to examine compliance with
the surgical protocol in the ST03 trial, and to review
whether surgical procedure influenced outcome, irrespec-
tive of perioperative treatment group. This is particularly
important in view of the overall similar outcomes between
the trial arms, as differences in surgical procedures could
have confounded any treatment effect in the trial.
Methods
The MRC ST03 trial was a randomized phase II–III
open-label comparison of perioperative epirubicin, cis-
platin and capecitabine (ECX) with ECX and bevacizumab
(ECX-B) in patients with operable oesophagogastric ade-
nocarcinoma. The trial began in 2007, completed recruit-
ment in 2014 and recruited 1063 patients; no significant
difference in overall survival was demonstrated between
the two arms of the trial11.
Surgery
At trial entry, all patients were considered operable and fit
for surgical resection. Eligibility criteria have been detailed
previously11. Patients entered into the trial included those
with adenocarcinoma of the stomach, OGJ (Siewert types
I, II and III) and lower oesophagus. Staging at diagno-
sis required spiral or multislice CT with laparoscopy for
all patients with gastric tumours and Siewert II and III
OGJ cancers, as well as for patients with Siewert type I
and lower oesophageal cancers if indicated clinically. Endo-
scopic ultrasound examination was recommended for all
lower oesophageal and Siewert type I, II or III cancers,
and performed according to local practice for all other can-
cers. PET–CT and MRI were recommended where clin-
ically indicated according to local practice. Eligible stages
were based on the sixth edition of the TNM classification13
(stomach, Siewert type III OGJ: stage Ib, II, III and IV
with no evidence of distant metastases; oesophagus (lower
third, Siewert types II and III): stage II to IVa), includ-
ing those with positive coeliac axis nodes if the surgeon
believed that R0 resection could be achieved. The trial
protocol stipulated pathological staging according to the
TNM sixth edition initially, but this was changed to the
seventh edition12 during the trial with appropriate protocol
amendment. For patients treated with ECX, surgery was
planned for 5–6weeks after the completion of preopera-
tive chemotherapy; for those who had ECX-B, surgery was
scheduled 8weeks after the last dose of bevacizumab.
Recommended surgical procedures
At the time of trial initiation, oesophageal and gastric can-
cer surgery had been centralized in specialist centres across
the UK, with experienced surgeons working in multi-
disciplinary teams that specialized in the management
of patients with upper gastrointestinal cancer. Many sur-
geons and oncologists had taken part in the previous
ST012, ST02 (MAGIC)10 and OE0214 trials. In view of
this experience, the protocol did not mandate any fur-
ther quality assessment other than the following procedure
descriptions15.
For gastric and Siewert type III cancers, acceptable resec-
tion methods included proximal gastrectomy for Siewert
type III cancers and cancers of the cardia; total gastrectomy
for Siewert type III cancers and cancers of the cardia, fun-
dus or body; and distal subtotal gastrectomy for cancers of
the antrum. Combined resection of other organs was per-
mitted if required to achieve completemacroscopic tumour
resection. In both total and distal gastrectomy, the greater
omentum was removed. For Siewert type II cancers, either
extended gastrectomy or two-phase oesophagogastrectomy
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 1204–1215
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was recommended at the surgeon’s discretion. For
lower oesophageal and Siewert type I OGJ tumours,
oesophagogastrectomy, either as a two-phase right tho-
racoabdominal approach or a left thoracoabdominal
approach, was recommended. Removal of sufficient crural
fibres and a cuff of diaphragm, together with the pericardial
fat pad and adjacent strips of parietal pleura, was recom-
mended to minimize the risk of a positive radial resection
margin.
Acceptable methods of reconstruction according to the
surgeon’s preference included oesophagogastrostomy,
oesophagojejunostomy (Roux-en-Y), oesophagojejuno-
gastrostomy (jejunal interposition), gastrojejunostomy
(Roux-en-Y or Billroth II) and gastrojejunoduodenostomy
(jejunal interposition). Anastomotic techniques included
handsewn, stapled or combined approaches.
The recommended extent of lymphadenectomy was
determined by the location of the primary tumour and
the type of resection. The protocol mandated the removal
of additional lymph nodes from other lymph node sta-
tions to ensure that the total number of lymph nodes
excised exceeded 15. A formal D2 dissection was the
preferred option for gastric and Siewert type III can-
cers, although D3–4 dissections were allowed (Table S1,
supporting information). A two-field lymphadenectomy
was described in the protocol for lower oesophageal and
Siewert type I and II cancers. This included removal of
lymph node stations 1, 2, 3, 7, 8 and 11 via the abdomen.
In the thoracic phase, paraoesophageal and diaphragmatic
lymph nodes (stations 108, 110 and 111) should ideally be
removed en bloc in continuity with the lower oesophagus
and lymph nodes at the tracheal bifurcation and along
the right and left main bronchi to the pulmonary hilus
(stations 107 and 109). The surgical clinical report form
required recording of the extent of lymph node dissection
as one group of lymph node stations and did not allow
for dissection of multiple stations (Table S2, supporting
information).
The option of a minimally invasive approach was
included if specific eligibility criteria for this type of pro-
cedure were met. The Trial Management Group (TMG)
determined that, for totally minimally invasive procedures,
surgeons should provide summary evidence of their pre-
vious 20 minimally invasive operations, including total
gastrectomy and oesophagogastrectomy, with details of
lymph node yields in both the abdomen and the media-
stinum and postoperative complication rates. A hybrid
approach of an open chest procedure combined with
a laparoscopic abdominal procedure was permitted for
lower oesophageal, and Siewert type I and II OGJ cancers,
without review of previous cases.
Pathology
The ST03 trial protocol included a detailed briefing doc-
ument for local pathologists to ensure standardized local
pathology procedures and high-quality pathology in all
centres. Pathological staging was initially done accord-
ing to the sixth edition of the TNM classification13, but
changed to the seventh edition12 once this had been pub-
lished, with appropriate trial protocol modification. Patho-
logical reporting of pretreatment biopsy and resection
specimens was based largely on the WHO classifica-
tion of digestive tumours (4th edition)16, the Royal Col-
lege of Pathologists data sets for oesophageal and gastric
cancer17,18 and other relevant literature. As a result, the
trial pathology reporting pro forma required details of T
category (including macroscopic and histological detail),
N status (based on number of nodes examined and num-
ber positive) and histologically confirmed distant metas-
tases. In addition, assessment of tumour response using
the Mandard system19 and resection margin involvement
(longitudinal and circumferential, defined as viable tumour
within 1mm of the margin) was required. Following full
reporting of the pathology of the resected specimen and
review at the local multidisciplinary team meeting, centres
were asked to send all haematoxylin and eosin-stained his-
tological slides of pretreatment biopsies and the resected
specimens, together with the respective reports and photo-
graphic documentation, for central pathological review.
Analysis
Details of surgery and the postoperative clinical course
were recorded prospectively on case report forms, which
were analysed at the MRC Clinical Trials Unit at Univer-
sity College London.
All toxicity in the trial was reported according to Com-
mon Terminology Criteria for Adverse Events (CTC-AE)
version 3.020, then grouped by organ system. Specific
surgery-related postoperative complications in the data
set included intraoperative events, anastomotic leak
(clinical versus radiological), return to surgery, intesti-
nal obstruction, pancreatic fistula and intra-abdominal
sepsis. Anastomotic leaks were recorded as clinical,
radiological/endoscopic or both clinical and radiolog-
ical/endoscopic. General postoperative complications
included cardiorespiratory and thromboembolic events,
sepsis and renal dysfunction. Pathology-related outcomes
were measured using lymph node yield and resection
margin involvement.
All data were tabulated and summarized (with either per-
centages or median (i.q.r.), as appropriate) according to
treatment group and in the trial as a whole. No comparative
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 1204–1215
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Fig. 1 Flow diagram for ST03 trial
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ECX, epirubicin, cisplatin and capecitabine; B, bevacizumab.
statistical tests were undertaken as the trial was not pow-
ered for these outcomes, and this was not the purpose of
the present analysis.
Results
Of 895 patients who underwent resectional surgery in the
ST03 trial (84⋅2 per cent of 1063 randomized), surgical
details were available for 880 (98⋅3 per cent) (Fig. 1 and
Table 1). There was no difference in surgical approaches
across the arms of the trial. Open surgery was performed
in 547 patients (62⋅2 per cent), and a minimally invasive
approach in 222 (25⋅2 per cent), which was either a totally
minimally invasive procedure (49, 5⋅6 per cent), a hybrid
approach (laparoscopic abdomen and open thoracotomy:
110, 12⋅5 per cent) or a laparoscopically assisted procedure
(63, 7⋅2 per cent). Data on surgical approach were missing
for 77 patients (8⋅8 per cent). Extended lymphadenectomy
including perigastric, left gastric, hepatic and splenic artery
lymph nodes was performed according to the surgeon’s
discretion in 46⋅6 per cent of patients, which was similar
in both trial arms (Table S2, supporting information).
Sites undertaking total minimally invasive laparoscopic
operations routinely within the trial were required to
provide information on their previous experience with
these techniques. Evidence was submitted for 67 of
112 operations at 14 sites. Of the remaining 45 oper-
ations, five were performed just once by centres and
noted as a protocol deviation. The surgical requirements
were followed by sites in 95⋅5 per cent of resection
procedures.
Some 159 patients completed preoperative chemother-
apy but did not undergo resection. Fifty-four of these
patients had surgery, which comprised a laparotomy only
(51 patients) or a laparotomy and bypass procedure (3
patients). The remaining patients did not undergo surgery
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 1204–1215
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Table 1 Surgical procedures and techniques
ECX (n = 450) ECX-B (n = 430) Total (n = 880)
Surgical procedure
Oesophagogastrectomy 235 (52⋅2) 224 (52⋅1) 459 (52⋅2)
Total gastrectomy 142 (31⋅6) 130 (30⋅2) 272 (30⋅9)
Subtotal gastrectomy 16 (3⋅6) 17 (4⋅0) 33 (3⋅8)
Proximal gastrectomy 1 (0⋅2) 1 (0⋅2) 2 (0⋅2)
Distal gastrectomy 44 (9⋅8) 44 (10⋅2) 88 (10⋅0)
Other 12 (2⋅7) 14 (3⋅3) 26 (3⋅0)
Surgical technique
Open surgery 275 (61⋅1) 272 (63⋅3) 547 (62⋅2)
Laparoscopically assisted surgery 36 (8⋅0) 27 (6⋅3) 63 (7⋅2)
Laparoscopic abdomen and open chest 59 (13⋅1) 51 (11⋅9) 110 (12⋅5)
Laparoscopic abdomen and thoracoscopic chest 26 (5⋅8) 23 (5⋅3) 49 (5⋅6)
Other 12 (2⋅7) 22 (5⋅1) 34 (3⋅9)
Missing 42 (9⋅3) 35 (8⋅1) 77 (8⋅8)
Values in parentheses are percentages. ECX, epirubicin, cisplatin and capecitabine; B, bevacizumab.
Table 2 Summary of postoperative complications
ECX (n = 446) ECX-B (n = 427) Total (n = 873)
All postoperative complications (maximum severity)
None 231 (51⋅8) 184 (43⋅1) 415 (47⋅5)
Non-life-threatening 178 (39⋅9) 209 (48⋅9) 387 (44⋅3)
Life-threatening 37 (8⋅3) 34 (8⋅0) 71 (8⋅1)
Notable events (maximum severity)
None 369 (82⋅7) 330 (77⋅3) 699 (80⋅1)
Non-life-threatening 62 (13⋅9) 81 (19⋅0) 143 (16⋅4)
Life-threatening 15 (3⋅4) 16 (3⋅7) 31 (3⋅6)
Other complications, not notable events (maximum severity)
None 245 (54⋅9) 213 (49⋅9) 458 (52⋅5)
Non-life-threatening 172 (38⋅6) 187 (43⋅8) 359 (41⋅1)
Life-threatening 29 (6⋅5) 27 (6⋅3) 56 (6⋅4)
Revisional operations
No 406 (91⋅0) 390 (91⋅3) 796 (91⋅2)
Yes 39 (8⋅7) 37 (8⋅7) 76 (8⋅7)
Unknown 1 (0⋅2) 0 (0) 1 (0⋅1)
Death before discharge from hospital
No 432 (96⋅9) 414 (97⋅0) 846 (96⋅9)
Yes 12 (2⋅7) 11 (2⋅6) 23 (2⋅6)
Unknown 2 (0⋅4) 2 (0⋅5) 4 (0⋅5)
Values in parentheses are percentage of patients with postoperative assessment details available; this information was missing for 11 patients who underwent
surgery in each group. ECX, epirubicin, cisplatin and capecitabine; B, bevacizumab.
because of disease progression, patient preference or for a
number of other reasons.
Postoperative complications
Postoperative morbidity and mortality after resection are
summarized in Table 2. Postoperative assessment details
were available for 97⋅5 per cent of operated patients (873
of 895). There were 24 deaths (2⋅7 per cent) within 30 days
of surgery and 33 (3⋅7 per cent) within 90 days. There
were no deaths within 30 days among those who under-
went laparotomy alone and were found to be inoperable
(Table S3, supporting information).
Complications were recorded as wound-related, includ-
ing wound healing, wound infection, intra-abdominal
sepsis and haemorrhage, or respiratory, including pleural
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 1204–1215
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Table 3 Postoperative complications by type
ECX (n = 446) ECX-B (n = 427) Total (n = 873)
Wound healing complications
No 413 (92⋅6) 374 (87⋅6) 787 (90⋅1)
Present but not life-threatening 30 (6⋅7) 48 (11⋅2) 78 (8⋅9)
Life-threatening 3 (0⋅7) 5 (1⋅2) 8 (0⋅9)
Superﬁcial wound infection
No 409 (91⋅7) 389 (91⋅1) 798 (91⋅4)
Present but not life-threatening 35 (7⋅8) 37 (8⋅7) 72 (8⋅2)
Life-threatening 2 (0⋅4) 1 (0⋅2) 3 (0⋅3)
Deep wound infection
No 431 (96⋅6) 415 (97⋅2) 846 (96⋅9)
Present but not life-threatening 12 (2⋅7) 8 (1⋅9) 20 (2⋅3)
Life-threatening 3 (0⋅7) 4 (0⋅9) 7 (0⋅8)
Intra-abdominal sepsis
No 428 (96⋅0) 410 (96⋅0) 838 (96⋅0)
Present but not life-threatening 11 (2⋅5) 10 (2⋅3) 21 (2⋅4)
Life-threatening 7 (1⋅6) 7 (1⋅6) 14 (1⋅6)
Haemorrhage requiring transfusion or intervention
No 433 (97⋅1) 414 (97⋅0) 847 (97⋅0)
Present but not life-threatening 9 (2⋅0) 6 (1⋅4) 15 (1⋅7)
Life-threatening 4 (0⋅9) 7 (1⋅6) 11 (1⋅3)
Pleural effusion requiring treatment
No 396 (88⋅8) 386 (90⋅4) 782 (89⋅6)
Present but not life-threatening 45 (10⋅1) 35 (8⋅2) 80 (9⋅2)
Life-threatening 5 (1⋅1) 6 (1⋅4) 11 (1⋅3)
Empyema
No 437 (98⋅0) 409 (95⋅8) 846 (96⋅9)
Present but not life-threatening 8 (1⋅8) 14 (3⋅3) 22 (2⋅5)
Life-threatening 1 (0⋅2) 4 (0⋅9) 5 (0⋅6)
Respiratory failure
No 419 (93⋅9) 404 (94⋅6) 823 (94⋅3)
Present but not life-threatening 14 (3⋅1) 10 (2⋅3) 24 (2⋅7)
Life-threatening 13 (2⋅9) 13 (3⋅0) 26 (3⋅0)
Respiratory tract infection
No 374 (83⋅9) 356 (83⋅4) 730 (83⋅6)
Present but not life-threatening 66 (14⋅8) 64 (15⋅0) 130 (14⋅9)
Life-threatening 6 (1⋅3) 7 (1⋅6) 13 (1⋅5)
Pulmonary embolism
No 439 (98⋅4) 418 (97⋅9) 857 (98⋅2)
Present but not life-threatening 5 (1⋅1) 8 (1⋅9) 13 (1⋅5)
Life-threatening 2 (0⋅4) 1 (0⋅2) 3 (0⋅3)
Deep vein thrombosis
No 443 (99⋅3) 420 (98⋅4) 863 (98⋅9)
Present but not life-threatening 3 (0⋅7) 6 (1⋅4) 9 (1⋅0)
Life-threatening 0 (0) 1 (0⋅2) 1 (0⋅1)
Cardiac complications
No 423 (94⋅8) 397 (93⋅0) 820 (93⋅9)
Present but not life-threatening 15 (3⋅4) 24 (5⋅6) 39 (4⋅5)
Life-threatening 8 (1⋅8) 6 (1⋅4) 14 (1⋅6)
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 1204–1215
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Table 3 Continued
ECX (n = 446) ECX-B (n = 427) Total (n = 873)
MRSA
No 437 (98⋅0) 421 (98⋅6) 858 (98⋅3)
Present but not life-threatening 9 (2⋅0) 6 (1⋅4) 15 (1⋅7)
Other
No 337 (75⋅6) 309 (72⋅4) 646 (74⋅0)
Present but not life-threatening 95 (21⋅3) 100 (23⋅4) 195 (22⋅3)
Life-threatening 14 (3⋅1) 18 (4⋅2) 32 (3⋅7)
Values in parentheses are percentage of patients with postoperative assessment details available; this information was missing for 11 patients who underwent
surgery in each group. ECX, epirubicin, cisplatin and capecitabine; B, bevacizumab; MRSA, methicillin-resistant Staphylococcus aureus.
Table 4 Postoperative complications by procedure
Oesophagogastrectomy (n = 453) Total gastrectomy (n = 272) Subtotal gastrectomy* (n = 123) Other (n = 25)
Sepsis 80 (17⋅7) 51 (18⋅8) 20 (16⋅3) 7 (28)
Respiratory 145 (32⋅0) 45 (16⋅5) 12 (9⋅8) 9 (36)
Bleeding† 17 (3⋅8) 6 (2⋅2) 2 (1⋅6) 1 (4)
Thromboembolic 15 (3⋅3) 4 (1⋅5) 5 (4⋅1) 1 (4)
Cardiovascular 38 (8⋅4) 9 (3⋅3) 4 (3⋅3) 2 (8)
Other 137 (30⋅2) 57 (21⋅0) 21 (17⋅1) 12 (48)
Values in parentheses are percentages. *Includes subtotal, distal and proximal gastrectomies. †Requiring transfusion or intervention.
effusion, chest infection, thromboembolic, cardiac
and systemic infection. These were graded simply as
life-threatening or not life-threatening as judged clinically.
There was no apparent difference in the overall rates
of complications across the various surgical procedures.
Complications of any type occurred in 458 patients (52⋅5
per cent) (Table 3). The most common complications were
respiratory (211 patients, 24⋅2 per cent) and sepsis (158,
18⋅1 per cent). The most common respiratory compli-
cation was respiratory tract infection (143 patients, 16⋅4
per cent). Wound healing complications were seen in 86
patients (9⋅9 per cent) and superficial wound infections in
75 (8⋅6 per cent), and formed the bulk of the infectious
complications. Wound healing complications of any grade
were more common in patients treated with bevacizumab
than in the ECX group: 53 of 427 (12⋅4 per cent) versus
33 of 446 (7⋅4 per cent) respectively. Rates of respiratory
complications were higher among patients undergoing
oesophagogastrectomy (145, 32⋅0 per cent) than for other
procedures, whereas rates of septic complications were
similarly distributed across patients undergoing oeso-
phagogastrectomy, total or subtotal gastrectomy (Table 4).
Details about complications for those who had surgery
but did not undergo resection were available for 37
of 54 patients (Table S3, supporting information). Nine
of these patients developed complications, which were
cardiorespiratory or wound-related.
Surgical complications
Two specific indicators of technical complications were
evaluated: anastomotic leaks and return to theatre. Com-
bining both trial arms, the anastomotic leak rate was 13⋅5
per cent (118 of 873 patients with postoperative data avail-
able) (Table 5). Twenty-six patients had clinical leaks, 25
leaks were identified radiologically or endoscopically, and
65 were diagnosed clinically and confirmed radiologically
or endoscopically; in two patients the evidence for a leak
was unclear. After oesophagogastrectomy, the anastomotic
leak rate was higher in those randomized to ECX-B than
in the ECX group: 52 of 220 (23⋅6 per cent) versus 23
of 233 (9⋅9 per cent) respectively. There was no differ-
ence between groups in leak rates after any type of gas-
trectomy. The anastomotic leak rate was 10⋅2 per cent
(43 of 420) in patients undergoing a procedure other
than oesophagogastrectomy. The majority of leaks (80 of
118, 67⋅8 per cent) occurred within the first 10 days after
surgery.
Seventy-six patients (8⋅7 per cent) had to return to the
operating theatre in the initial postoperative period; this
occurred in the first week in 38 patients (50 per cent) and
in the second week in a further 20 (26 per cent). The
commonest reasons for reoperation were anastomotic leak
(18 patients, 24 per cent), and laparotomy (17, 22 per cent)
or thoracotomy (12, 16 per cent) for lavage to treat sepsis.
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Table 5 Anastomotic leak rates
ECX (n = 446) ECX-B (n = 427) Total (n = 873)
By tumour site at randomization
Lower oesophageal 7 of 65 (11) 16 of 59 (27) 23 of 124 (18⋅5)
OGJ, type I 5 of 57 (9) 10 of 53 (19) 15 of 110 (13⋅6)
OGJ, type II 11 of 87 (13) 12 of 71 (17) 23 of 158 (14⋅6)
OGJ, type III 6 of 75 (8) 19 of 88 (22) 25 of 163 (15⋅3)
Stomach 14 of 162 (8⋅6) 18 of 156 (11⋅5) 32 of 318 (10⋅1)
By surgical procedure
Oesophagogastrectomy 23 of 233 (9⋅9) 52 of 220 (23⋅6) 75 of 453 (16⋅6)
Total gastrectomy 18 of 139 (13⋅0) 19 of 129 (14⋅7) 37 of 268 (13⋅8)
Subtotal gastrectomy 0 of 16 (0) 1 of 17 (6) 1 of 33 (3)
Distal gastrectomy 1 of 43 (2) 2 of 43 (5) 3 of 86 (3)
Other 1 of 15 (7) 1 of 18 (6) 2 of 33 (6)
By surgical procedure (combined)
Oesophagogastrectomy 23 of 233 (9⋅9) 52 of 220 (23⋅6) 75 of 453 (16⋅6)
All other procedures 20 of 213 (9⋅4) 23 of 207 (11⋅1) 43 of 420 (10⋅2)
Overall 43 of 446 (9⋅6) 75 of 427 (17⋅6) 118 of 873 (13⋅5)
Values in parentheses are percentages. ECX, epirubicin, cisplatin and capecitabine; B, bevacizumab; OGJ, oesophagogastric junctional.
Table 6 Total number of lymph nodes retrieved from the resected specimen according to local pathologists
Total no. of lymph nodes ECX (n = 436) ECX+B (n = 409) Total (n = 845)
Median (i.q.r.) 24 (17–33) 25 (18–34) 24 (17–34)
Range 0–96 0–89 0–96
0 5 (1⋅1) 5 (1⋅2) 10 (1⋅2)
< 15 74 (17⋅0) 57 (13⋅9) 131 (15⋅5)
15–24 146 (33⋅5) 137 (33⋅5) 283 (33⋅5)
25–34 109 (25⋅0) 110 (26⋅9) 219 (25⋅9)
35–44 56 (12⋅8) 60 (14⋅7) 116 (13⋅7)
≥ 45 42 (9⋅6) 37 (9⋅0) 79 (9⋅3)
Unknown 4 (0⋅9) 3 (0⋅7) 7 (0⋅8)
Values in parentheses are percentages unless indicated otherwise. ECX, epirubicin, cisplatin and capecitabine; B, bevacizumab.
Surgical pathology
Details of pathological staging and response to chemother-
apy have been described previously11. Pathology results
were available for 845 patients (94⋅4 per cent of those
who underwent tumour resection). The median number
of lymph nodes dissected from the resection specimen by
the local pathologist was 24 (i.q.r. 17–34); this was similar
in both arms of the trial. At least 15 lymph nodes were
retrieved in 82⋅5 per cent of resection specimens, and 25 or
more lymph nodes in 49⋅0 per cent of specimens (Table 6).
Information on pathological resection margin status was
available for 834 patients; 626 of these patients (75⋅1 per
cent) had an R0 resection and 208 (24⋅9 per cent) had
a pathologically positive resection margin (R1) (Table S4,
supporting information). The majority with an R1 margin
(146 patients) had an oesophagogastrectomy, and 132 of
these patients had a positive circumferential (radial) mar-
gin. This equated to an R1 resection rate of 31⋅8 per cent
for all of the oesophagogastric resections. The remaining
R1 resections included proximal resection margin involve-
ment in 42 patients (20⋅2 per cent of all R1 resections) and
distal margin involvement in 33 (15⋅9 per cent).
Discussion
The ST03 trial was a national multicentre trial that
recruited patients at almost 100 hospitals in the UK
between 2007 and 2013. Its primary outcome was overall
survival between the two treatment arms. The trial had a
pragmatic design, with R0 resection as the only secondary
outcome measure with a surgical theme. As a result, spe-
cific details of surgical procedures were not recorded as in
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a trial comparing surgical procedures. This trial therefore
delivers a snapshot of UK contemporary surgical practice.
The ST03 surgical protocol was designed to prespecify
the surgical approaches and extent of resection to minimize
performance bias related to individual surgeon preference,
which may be influenced by tumour response to periop-
erative chemotherapy. The study included prospective
data collection on case report forms to record the type
of surgical procedure actually undertaken. Development
of the ST03 trial protocol was informed by best current
evidence. However, it was also pragmatic, thus allowing
flexibility in several components of the intervention (such
as minimal access or open surgery, extent of lymph node
dissection). High-quality pathological data were available
to relate surgical procedures to outcome measures, such
as lymph node yield and resection margin status, owing
to use of a prespecified histopathology protocol, which
included detailed guidance for local pathologists as well
as a comprehensive prospective data collection. This ana-
lysis showed that surgical procedures and outcomes were
similar in both arms of the trial. Therefore, heterogeneity
of surgical approach was unlikely to be responsible for the
lack of benefit observed in the experimental arm of the
trial.
The inclusion of minimally invasive surgery required a
protocol modification as such techniques were not com-
monplace at the inception of the trial. The TMG required
surgeons undertaking these procedures in patients entered
into the trial to provide evidence of their qualitative
outcomes. Despite this requirement, formal review by
the TMG was completed for only 28⋅1 per cent of the
minimally invasive procedures undertaken. Retrospective
review of the remaining patients showed no excess compli-
cation rates and equivalent lymph node yields, suggesting
consistency of the quality of the surgery.However, this does
highlight one of the challenges in a randomized trial where
protocol modifications may be required that could affect
outcome.
Despite comprehensive staging assessments at the time
of diagnosis and randomization into the trial, 15⋅8 per
cent of the trial population did not undergo resection,
with 5⋅1 per cent found to be inoperable at laparotomy.
The outcome for this group was not complicated by excess
postoperative morbidity. These levels of inoperability and
unresectability are important findings, which should be
explained to patients when entering into a trial21.
Surgeons performing operations and pathologists dis-
secting resection specimens within the context of the ST03
trial were highly compliant with respect to the protocol
requirement of resecting and retrieving a minimum of 15
lymph nodes; this goal was achieved in 82⋅5 per cent of
resections. Furthermore 25 or more lymph nodes were
retrieved by the pathologist in 49⋅0 per cent of resections.
Although pathological examination of the resected speci-
mens in the trial was based on Royal College of Patholo-
gists guidance, there are limitations in this data as lymph
node stations were not examined individually in the major-
ity of patients. Nevertheless, these lymph node harvest
figures show a definite increase compared with those in the
MAGIC trial10, in which 53 per cent of patients had more
than 15 nodes removed and 19 per cent had more than 25
excised. Notably, in the MAGIC trial, surgeons undertook
procedures at their discretion; the extent of lymphadenec-
tomywas not specified in theMAGIC trial protocol.More-
over, these lymph node yield figures are higher than those
reported in the Dutch CRITICS22 trial, in which 72⋅8 per
cent of resections were compliant with the protocol stip-
ulation of sampling a minimum of 15 nodes and 87⋅5 per
cent of patients had at least a D1+ resection. Furthermore,
the median number of nodes examined in CRITICS was
20 (range 0–72) contrasting with 24 (0–96) in ST03.
Surgery in the ST03 study was associated with a low
rate of postoperative mortality which, at 3⋅7 per cent at
90 days, is a further improvement in comparison with both
the MAGIC trial (ST02), in which the 90-day mortality
rate was 6 per cent, and theMRCST01 study, with hospital
mortality rates of 9 and 16 per cent after D1 and D2 total
gastrectomy respectively. The postoperative mortality rate
in ST03 was similar to that reported for oesophagectomy
and gastrectomy in the UK National Oesophago-Gastric
Cancer Audit (NOGCA)23, which records approximately
98 per cent of cases resected annually in the UK.
Despite these improvements in postoperative mortality
compared with earlier trials, there was a relatively high rate
of postoperative complications in ST03 (52⋅5 per cent of
all patients). However, this figure describes all levels of the
spectrum of complications, including many that did not
require clinical intervention. This represents a limitation of
the present study and is a reflection of the protocol, which
was developed before more specific definition of compli-
cations was standardized. The authors therefore advocate
use of a systematic classification such as theClavien–Dindo
classification24 in future trials as well as consensus guid-
ance on recording complications25,26. In addition, patients
undergoing oesophageal and gastric cancer resection have
established co-morbidity, and optimization of pulmonary
function should be standard practice in the context of pre-
habilitation and enhanced recovery approaches to mini-
mize predictable postoperative complications.
Overall compliance with the protocol in ST03 represents
a definite improvement in surgical and pathology practice
compared with previous studies. However, it is important
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to recognize that surgery within the ST03 trial was sub-
ject to a number of other significant changes in practice.
The trial was undertaken during the time of reconfigura-
tion of surgical services for oesophageal and gastric cancer
in the UK, which included greater prominence of multi-
disciplinary team management for all patients. In addition,
there was enhanced surgical and pathology specialization
as well as advances in critical and intensive care treatments.
The inclusion of minimally invasive techniques required a
careful review of practice and outcomes for those wishing
to use these procedures in the context of their established
expertise. Themajority of surgeons had contributed to pre-
vious multicentre studies (ST01, ST02 and OE05). It was
acknowledged that their adherence to the protocol would
not be problematic, and specific evidence of their prac-
tice and outcomes was not considered necessary. Data from
audits have clearly shown improvements and consistency
in overall outcome with the emphasis on quality assurance
and publication of individual-surgeon outcomes. The prag-
matic nature of this trial has shown how large multicentre
trials can be undertaken effectively with consistent out-
comes.
Two challenges are highlighted by the ST03 results.
The first of these, the high rate of anastomotic leak in
patients who underwent oesophagogastrectomy after treat-
ment with bevacizumab (23⋅6 per cent), is unique to the
present trial. This inflated the overall rate of anastomotic
leakage to 13⋅5 per cent, which compares unfavourably
with 7 per cent in the NOGCA data set. However, the
overall reoperation rate of 8⋅7 per cent is comparable to
rates of 9⋅8 per cent for oesophagectomy and 8⋅1 per cent
for gastrectomy recorded in the NOGCA23. Despite care-
ful evaluation of all potential variables, it was not possi-
ble to explain the difference in leak rate between patients
who received bevacizumab and those who did not, and
it is currently considered to represent a potential adverse
effect on local healing secondary to microvascular insuffi-
ciency related to treatment with bevacizumab. Consider-
ation of other data and sensitivity analyses did not pro-
vide any indication that this excess rate of anastomotic
leakage had a substantial effect on the overall primary
outcome of the trial; the Independent Data Monitoring
Committee had reviewed the data when this rate was iden-
tified and stopped recruitment of patients scheduled for
oesophagogastrectomy.
The second challenge is the relatively high rate of R1
resections (25⋅1 per cent) in the trial (gastrectomy 15⋅7
per cent and oesophagogastrectomy 31⋅8 per cent). The
majority of positive margins (90⋅4 per cent for oesoph-
agogastrectomies) were circumferential. Similar results
have been reported in the contemporaneous OE05 study27,
in which the R1 rate was 34 per cent. The OE05 protocol
specified the extent of dissection at the diaphragmatic
hiatus to include resection of a cuff of diaphragm and both
parietal pleura adjacent to the OGJ. Compliance with
this aspect of the protocol has not been determined in
the present trial. However, lower rates of circumferential
resection margins have been described in surgical series
with more radical procedures. In CROSS (ChemoRa-
diotherapy for Oesophageal cancer followed by Surgery
Study)28, the R1 rate in the chemoradiotherapy arm was
8 per cent compared with 30 per cent in the control
surgery-only arm. There is thus a challenge to deter-
mine whether more standardized surgery can achieve
R0 rates similar to those achieved after neoadjuvant
chemoradiotherapy. However, the high R0 rate in the
treatment arm of the CROSS trial may reflect the effect
of chemoradiotherapy as well as the fact that patients
with adenocarcinoma and those with squamous cell car-
cinoma were included in the trial. Furthermore, more
contemporary taxane-containing preoperative chemother-
apy regimens such as FLOT (5-fluorouracil, oxaliplatin
and docetaxel) seem to be associated with improved R0
resection rates compared with the anthracycline-based
regimens used in ST03 and OE0529. This is of particular
relevance, as the survival benefit of chemoradiotherapy
over perioperative chemotherapy is still unclear. Ongoing
clinical trials are currently addressing this issue. The results
of these studies and assessment of response to neoadjuvant
therapy are likely to affect selection of patients who have
the greatest chance of benefit from operative intervention.
The present analysis has shown that surgery in the ST03
trial was performed to a higher standard than in previous
similar UK trials, in terms of postoperative mortality and
lymphadenectomy, which also reflects a higher standard of
pathology reporting. This was consistent across both treat-
ment arms, indicating that surgery had no effect on the
overall outcome of the trial. The rates of postoperative
complications were high, partly reflecting the inclusion of
all grades of morbidity, although few patients developed
life-threatening complications. There remains the chal-
lenge of achieving a higher rate of R0 resection to com-
plement the benefits of perioperative strategies.
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